 STOCKHOLM, March 25, 2021 PRNewswire -- Medivir AB Nasdaq Stockholm: MVIR today announced that the last patient with advanced liver cancer has been included in the first part of the phase Ib study with MIV-818. Like the other patients in the study, the patient is dosed in cycles of three weeks starting with MIV-818 as monotherapy for five days. 